

Tel. : (91 832) 2257253 / 6714444

Fax : (91 832) 2257044 E-mail: gkbophthalmics@gkb.net

Website: www.gkb.net

GKB/STK-EXCH November 11, 2021

To, The Listing Department **BSE** Limited Phiroze Jeejubhoy Towers, Dalal Street Mumbai - 400 001

Dear Sir,

Ref: Scrip Code No.: 533212

Sub: Statement of deviation(s) or variation(s) under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements ) Regulations , 2015

Pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019, dated December 24, 2019, we would like to inform you that the Audit Committee in their meeting held on November 11, 2021, has reviewed the utilisation of funds which were raised by means of preferential allotment and noted that there was no utilization of funds, during the quarter ended September 30, 2021.

Enclosed please find the Statement as per the format, giving details of the same.

Kindly take the information on records.

MAPUSA GOA

Thanking you

Yours faithfully,

For GKB Ophthalmics Limited MIC

Pooja Bicholkar

Company Secretary



## Statement of Deviation / Variation in utilisation of funds raised

Name of listed entity	GKB Ophthalmics Limited		
Mode of Fund Raising	Public Issues / Rights Issues / Preferential		
Mode of Fund Raising	Issues / QIP / Others		
Date of Raising Funds	July 27, 2018 and January 22, 2020		
Amount Raised	Equity Shares - Rs. 7,54,85,000		
Amount Ruised	Warrants - Rs. 2,90,62,500		
	Warrants - Rs. 4,65,00,000 (75% of balance		
	warrant money received on or before		
	January 21, 2020, with respect to 4,00,000		
	warrants)		
Report filed for Quarter ended	September 30, 2021		
Monitoring Agency	applicable / not applicable		
Monitoring Agency Name, if applicable	Yes / No		
Is there a Deviation / Variation in use of funds raised	No. There is no utilization of funds for the		
is there a between f	quarter ended September 30, 2021.		
If yes, whether the same is pursuant to change in terms of a contract			
or objects, which was approved by the shareholders			
If Yes, Date of shareholder Approval			
Explanation for the Deviation / Variation			
Comments of the Audit Committee after review	The Audit Committee noted that there was		
	no utilization of funds for the quarter		
	ended September 30, 2021.		
Comments of the auditors, if any			



Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variati on for the quarter according to applicable object	Remarks, if any
The Company will utilize the funds raised through preferential issue to scale up the operations in the present business, to fund the future growth plans of the Company both organically or inorganically, also to meet long term capital requirements of the Company and other general corporate purpose.	N.A	15.10 Crores	N.A	15.04 Crores	N.A	N.A

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Pooja Bicholkar Company Secretary